Novartis announced today that is has entered into an agreement to acquire AveXis, Inc., a clinical stage gene therapy company for $8.7 billion in cash. AveXis lead product candidate, AVXS-101, has potential to be first-ever one-time gene replacement therapy for spinal muscular atrophy (SMA), a disease which results in early death or lifelong disability with considerable healthcare costs. It is estimated that one out of every 6,000-10,000 children born is affected by some form of SMA.The US Food
Read More
gene therapy
IBM Watson, Quest Diagnostics Partner to Offer Gene Sequencing Service
IBM Watson is teaming up with Quest Diagnostics to launch Watson Genomics from Quest Diagnostics, a gene sequencing and Watson diagnostic analysis service to help oncologists deliver precision medicine to their patients. Together with Memorial Sloan Kettering Cancer Center (MSK), the service will provide a personalized tumor analysis of a patient’s sequenced genomic tumor that is supported by clinical evidence. As part of the precision medicine partnership, The Broad Institute of MIT and Harvard
Read More
Mayo Clinic, GE Ventures Partner to Bring IoT Approach to Cell, Gene Therapies
Today, GE Ventures and Mayo Clinic announced they are teaming up to launch Vitruvian Networks, Inc., an independent platform company committed to accelerating access to cell and gene therapies through advanced, cloud-ready software systems and manufacturing services. Vitruvian Networks will partner with therapy producers and serve them by providing a state-of-the-art software and manufacturing platform to bring the Internet of Things (IoT) to cell and gene therapies. At scale, the platform will
Read More
